Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 242

1.

Targeting the MYCN-PARP-DNA Damage Response Pathway inNeuroendocrine Prostate Cancer.

Zhang W, Liu B, Wu W, Li L, Broom BM, Basourakos SM, Korentzelos D, Luan Y, Wang J, Yang G, Park S, Azad AK, Cao X, Kim J, Corn P, Logothetis C, Aparicio AM, Chinnayan AM, Navone NM, Troncoso P, Thompson TC.

Clin Cancer Res. 2017 Nov 14. pii: clincanres.1872.2017. doi: 10.1158/1078-0432.CCR-17-1872. [Epub ahead of print]

PMID:
29138344
2.

High-grade neuroendocrine carcinoma of the urachus-report of 3 cases.

Wang G, Huang H, Kamat AM, Siefker-Radtke A, Dinney CP, Troncoso P, Czerniak B, Guo CC.

Hum Pathol. 2017 Sep;67:126-133. doi: 10.1016/j.humpath.2017.08.003. Epub 2017 Aug 18.

PMID:
28823575
3.

Salvage prostatectomy for post-radiation adenocarcinoma with treatment effect: Pathological and oncological outcomes.

Metcalfe MJ, Troncoso P, Guo CC, Chen HC, Bozkurt Y, Ward JF, Pisters LL.

Can Urol Assoc J. 2017 Jul;11(7):E277-E284. doi: 10.5489/cuaj.4304. Epub 2017 Jul 11.

4.

Baseline and longitudinal plasma caveolin-1 level as a biomarker in active surveillance for early-stage prostate cancer.

Basourakos SP, Davis JW, Chapin BF, Ward JF, Pettaway CA, Pisters LL, Navai N, Achim MF, Wang X, Chen HC, Choi S, Kuban D, Troncoso P, Hanash S, Thompson TC, Kim J.

BJU Int. 2017 Jul 15. doi: 10.1111/bju.13963. [Epub ahead of print]

PMID:
28710901
5.

Genetic ancestry and prostate cancer susceptibility SNPs in Puerto Rican and African American men.

Irizarry-Ramírez M, Kittles RA, Wang X, Salgado-Montilla J, Nogueras-González GM, Sánchez-Ortiz R, Guerrios L, Rivera K, Shah E, Prokhorova I, Roberson P, Troncoso P, Pettaway CA.

Prostate. 2017 Jul;77(10):1118-1127. doi: 10.1002/pros.23368. Epub 2017 May 24.

PMID:
28543179
6.

Androgen receptor inhibitor-induced "BRCAness" and PARP inhibition are synthetically lethal for castration-resistant prostate cancer.

Li L, Karanika S, Yang G, Wang J, Park S, Broom BM, Manyam GC, Wu W, Luo Y, Basourakos S, Song JH, Gallick GE, Karantanos T, Korentzelos D, Azad AK, Kim J, Corn PG, Aparicio AM, Logothetis CJ, Troncoso P, Heffernan T, Toniatti C, Lee HS, Lee JS, Zuo X, Chang W, Yin J, Thompson TC.

Sci Signal. 2017 May 23;10(480). pii: eaam7479. doi: 10.1126/scisignal.aam7479.

PMID:
28536297
7.

Erratum: Effective combinatorial immunotherapy for castration-resistant prostate cancer.

Lu X, Horner JW, Paul E, Shang X, Troncoso P, Deng P, Jiang S, Chang Q, Spring DJ, Sharma P, Zebala JA, Maeda DY, Wang YA, DePinho RA.

Nature. 2017 May 3;545(7652):116. doi: 10.1038/nature22348. No abstract available.

PMID:
28470201
8.

VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer.

Gao J, Ward JF, Pettaway CA, Shi LZ, Subudhi SK, Vence LM, Zhao H, Chen J, Chen H, Efstathiou E, Troncoso P, Allison JP, Logothetis CJ, Wistuba II, Sepulveda MA, Sun J, Wargo J, Blando J, Sharma P.

Nat Med. 2017 May;23(5):551-555. doi: 10.1038/nm.4308. Epub 2017 Mar 27.

PMID:
28346412
9.

Effective combinatorial immunotherapy for castration-resistant prostate cancer.

Lu X, Horner JW, Paul E, Shang X, Troncoso P, Deng P, Jiang S, Chang Q, Spring DJ, Sharma P, Zebala JA, Maeda DY, Wang YA, DePinho RA.

Nature. 2017 Mar 30;543(7647):728-732. doi: 10.1038/nature21676. Epub 2017 Mar 20. Erratum in: Nature. 2017 May 3;545(7652):116.

10.

Targeting DNA Damage Response in Prostate Cancer by Inhibiting Androgen Receptor-CDC6-ATR-Chk1 Signaling.

Karanika S, Karantanos T, Li L, Wang J, Park S, Yang G, Zuo X, Song JH, Maity SN, Manyam GC, Broom B, Aparicio AM, Gallick GE, Troncoso P, Corn PG, Navone N, Zhang W, Li S, Thompson TC.

Cell Rep. 2017 Feb 21;18(8):1970-1981. doi: 10.1016/j.celrep.2017.01.072.

11.

Synthetic essentiality of chromatin remodelling factor CHD1 in PTEN-deficient cancer.

Zhao D, Lu X, Wang G, Lan Z, Liao W, Li J, Liang X, Chen JR, Shah S, Shang X, Tang M, Deng P, Dey P, Chakravarti D, Chen P, Spring DJ, Navone NM, Troncoso P, Zhang J, Wang YA, DePinho RA.

Nature. 2017 Feb 23;542(7642):484-488. doi: 10.1038/nature21357. Epub 2017 Feb 6.

12.

Transformation of prostatic adenocarcinoma to well-differentiated neuroendocrine tumor after hormonal treatment.

Gilani S, Guo CC, Li-Ning EM, Pettaway C, Troncoso P.

Hum Pathol. 2017 Jun;64:186-190. doi: 10.1016/j.humpath.2017.01.006. Epub 2017 Jan 31.

PMID:
28159676
13.

High risks of lung disease associated with early-life and moderate lifetime arsenic exposure in northern Chile.

Steinmaus C, Ferreccio C, Acevedo J, Balmes JR, Liaw J, Troncoso P, Dauphiné DC, Nardone A, Smith AH.

Toxicol Appl Pharmacol. 2016 Dec 15;313:10-15. doi: 10.1016/j.taap.2016.10.006. Epub 2016 Oct 8.

PMID:
27725189
14.

Targeted molecular-genetic imaging and ligand-directed therapy in aggressive variant prostate cancer.

Ferrara F, Staquicini DI, Driessen WH, D'Angelo S, Dobroff AS, Barry M, Lomo LC, Staquicini FI, Cardó-Vila M, Soghomonyan S, Alauddin MM, Flores LG 2nd, Arap MA, Lauer RC, Mathew P, Efstathiou E, Aparicio AM, Troncoso P, Navone NM, Logothetis CJ, Marchiò S, Gelovani JG, Sidman RL, Pasqualini R, Arap W.

Proc Natl Acad Sci U S A. 2016 Oct 24. pii: 201615400. [Epub ahead of print]

15.

Paired High-Content Analysis of Prostate Cancer Cells in Bone Marrow and Blood Characterizes Increased Androgen Receptor Expression in Tumor Cell Clusters.

Carlsson A, Kuhn P, Luttgen MS, Dizon KK, Troncoso P, Corn PG, Kolatkar A, Hicks JB, Logothetis CJ, Zurita AJ.

Clin Cancer Res. 2017 Apr 1;23(7):1722-1732. doi: 10.1158/1078-0432.CCR-16-1355. Epub 2016 Oct 4.

PMID:
27702818
16.

[The legal framework to prevent teenage pregnancies].

Leal I, Luttges C, Troncoso P, Leyton C, Molina T, Eguiguren P.

Rev Med Chil. 2016 May;144(5):577-84. doi: 10.4067/S0034-98872016000500004. Spanish.

17.

[Maternal infection due to Helicobacter pylori does not increase the risk of the infection in the first trimester of the life of their infants].

Troncoso P, Villagrán A, Vera M, Estay A, Ortiz M, Serrano C, Hernández C, Harris PR.

Rev Chil Pediatr. 2016 Nov - Dec;87(6):474-479. doi: 10.1016/j.rchipe.2016.06.002. Epub 2016 Jul 15. Spanish.

18.

Caveolin-1 regulates hormone resistance through lipid synthesis, creating novel therapeutic opportunities for castration-resistant prostate cancer.

Karantanos T, Karanika S, Wang J, Yang G, Dobashi M, Park S, Ren C, Li L, Basourakos SP, Hoang A, Efstathiou E, Wang X, Troncoso P, Titus M, Broom B, Kim J, Corn PG, Logothetis CJ, Thompson TC.

Oncotarget. 2016 Jul 19;7(29):46321-46334. doi: 10.18632/oncotarget.10113.

19.

Tissue Effects in a Randomized Controlled Trial of Short-term Finasteride in Early Prostate Cancer.

Kim J, Davis JW, Klein EA, Magi-Galluzzi C, Lotan Y, Ward JF, Pisters LL, Basler JW, Pettaway CA, Stephenson A, Li Ning Tapia EM, Efstathiou E, Wang X, Do KA, Lee JJ, Gorlov IP, Vornik LA, Hoque AM, Prokhorova IN, Parnes HL, Lippman SM, Thompson IM, Brown PH, Logothetis CJ, Troncoso P.

EBioMedicine. 2016 May;7:85-93. doi: 10.1016/j.ebiom.2016.03.047. Epub 2016 Apr 7.

20.

CXCL1 mediates obesity-associated adipose stromal cell trafficking and function in the tumour microenvironment.

Zhang T, Tseng C, Zhang Y, Sirin O, Corn PG, Li-Ning-Tapia EM, Troncoso P, Davis J, Pettaway C, Ward J, Frazier ML, Logothetis C, Kolonin MG.

Nat Commun. 2016 May 31;7:11674. doi: 10.1038/ncomms11674.

Supplemental Content

Loading ...
Support Center